Distribution of glutathione peroxidase 1 in liver tissues of healthy and diabetic rats treated with capsaisin

• Published in: Biotechnic & histochemistry Vol. 90; no. 1; p. 1
• Main Authors: Deprem, T, Yıldız, S E, Sari, E K, Bingol, S A, Tasci, S K, Aslan, S, Sozmen, M, Nur, G
• Format: Journal Article
• Language: English
• Published: England 01-01-2015
• Subjects: Animals; Antioxidants - pharmacology; Blood Glucose - drug effects; Blood Glucose - metabolism; Capsaicin - pharmacology; Diabetes Mellitus, Experimental - drug therapy; Diabetes Mellitus, Experimental - enzymology; Female; Glutathione Peroxidase - metabolism; Hepatocytes - enzymology; Liver - enzymology; Liver - pathology; Oxidative Stress - drug effects; Oxidative Stress - physiology; Rats, Sprague-Dawley; Streptozocin - pharmacology; diabetes mellitus; immunohistochemistry; glutathione peroxidase 1; liver; GPx 1; capsaisin
• ISSN: 1473-7760
• DOI: 10.3109/10520295.2014.919024

We investigated the immunohistochemical localization of glutathione peroxidase 1 (GPx 1) and the structural changes that occur in the livers of healthy and diabetic rats that were treated with capsaisin (CAP). Fifty female rats were divided into five groups: group 1, sham; group 2, untreated control; group 3, CAP-treated; group 4, streptozotocin (STZ) diabetic; group 5, STZ diabetic + CAP-treated. STZ was administered to groups 4 and 5; after verifying diabetes, CAP was administered daily for 2 weeks to groups 3 and 5. Diffuse, microvesicular and some macrovesicular fatty degeneration were observed in the cytoplasms of hepatocytes in the livers of the diabetic group. In the CAP-treated diabetic group, fat degeneration in the livers decreased slightly by day 7. Irregularity of the external contours of nuclei of the hepatocytes, swelling of the nuclei, and slight anisocytosis and anisokaryosis were observed in the hepatocytes of the diabetic group. In the CAP-treated diabetic groups, the severity of anisocytosis and anisokaryosis decreased slightly by day 7. In all groups, GPx 1 showed similar immunolocalization, but in the diabetic and diabetic + CAP groups, GPx 1 immunoreactivity was less than in the other groups. GPx 1 immunoreactivity in the CAP-treated diabetic group was weaker than in the diabetic group. In all groups, GPx 1 immunoreactivity was diffusely cytoplasmic in some of the hepatocytes, and diffusely cytoplasmic and diffusely nuclear in other hepatocytes. Also, GPx 1 immunoreactivity in the liver was more intense in the hepatocytes around Kiernan's space. We found that CAP caused a decrease in GPx 1.